Bellicum Pharmaceuticals, Inc. (BLCM)

NASDAQ: BLCM · IEX Real-Time Price · USD
1.24
0.00 (0.00%)
Feb 1, 2023, 12:00 AM EST - Market open
Market Cap 10.42M
Revenue (ttm) 1.50M
Net Income (ttm) -16.25M
Shares Out 8.61M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 735
Open 1.13
Previous Close 1.24
Day's Range 1.11 - 1.25
52-Week Range 0.60 - 2.20
Beta 1.38
Analysts Buy
Price Target 5.10 (+311.29%)
Earnings Date Mar 23, 2023

About BLCM

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trial... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2014
Employees 7
Stock Exchange NASDAQ
Ticker Symbol BLCM
Full Company Profile

Financial Performance

In 2021, BLCM's revenue was $6.20 million, an increase of 1140.00% compared to the previous year's $500,000. Losses were -$9.71 million, 25.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BLCM stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 311.29% from the latest price.

Price Target
$5.1
(311.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 4...

1 day ago - GlobeNewsWire

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducem...

1 day ago - GlobeNewsWire

Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium

HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstr...

2 weeks ago - GlobeNewsWire

Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster pres...

1 month ago - GlobeNewsWire

Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa

HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fai...

4 months ago - GlobeNewsWire

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fa...

5 months ago - GlobeNewsWire

Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Bellicum Pharmaceuticals (BLCM), indicating that the stock has found support. This, combined with an upward trend in earnings...

5 months ago - Zacks Investment Research

Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial resu...

6 months ago - GlobeNewsWire

Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study -

11 months ago - GlobeNewsWire

Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fai...

1 year ago - GlobeNewsWire

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has r...

1 year ago - GlobeNewsWire

Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies

Bellicum will issue pre-funded warrants to purchase up to 20.6 million shares and accompanying warrants to purchase up to 2.06 million shares at a combined unit price of $1.7024. Warrants have an exer...

1 year ago - Benzinga

Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology -

1 year ago - GlobeNewsWire

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fai...

1 year ago - GlobeNewsWire

Why Is Bellicum Stock Moving Higher On Wednesday?

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and The University of Texas MD Anderson Cancer Center have announced a global option and license agreement for Bellicum's CaspaCIDe (inducible caspase-9, or...

1 year ago - Benzinga

Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas M...

1 year ago - GlobeNewsWire

Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity indu...

1 year ago - GlobeNewsWire

Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered...

1 year ago - GlobeNewsWire

Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update

HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial resul...

1 year ago - GlobeNewsWire

Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update

Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2

2 years ago - GlobeNewsWire

Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT

2 years ago - GlobeNewsWire

Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publicati...

2 years ago - GlobeNewsWire

Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. ...

2 years ago - GlobeNewsWire

Bet on Rising P/E With These 5 Top-Ranked Stocks

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols: BJLMNLQFINVCNXVIVO
2 years ago - Zacks Investment Research

Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why

Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 years ago - Zacks Investment Research